BIOMAT Database Logo BIOMAT Database Logo

Diagnosis of hepatocellular carcinoma by concanavalin A affinity electrophoresis of serum alpha-fetoprotein. 1995

S Saitoh, and K Ikeda, and I Koida, and Y Suzuki, and M Kobayashi, and A Tsubota, and Y Arase, and K Chayama, and N Murashima, and H Kumada
Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan.

BACKGROUND Concanavalin A (Con A) affinity electrophoresis of serum alpha-fetoprotein (AFP) can distinguish hepatocellular carcinoma (HCC) from other malignancies when the serum AFP concentration is elevated. However, Con A has not been able to distinguish HCC from benign chronic liver disease such as cirrhosis or chronic hepatitis. METHODS The Con A affinity electrophoresis of serum AFP was analyzed in patients with a serum AFP concentration greater than 50 ng/mL by antibody affinity electrophoresis and Western blotting in an attempt to distinguish hepatocellular carcinoma from benign chronic liver disease. Before the assay, the serum AFP concentrations were adjusted between 100 ng/ml and 300 ng/ml by concentrating or diluting the samples. RESULTS Of 180 patients with HCC, 44 (24%) had a single band and 91 (51%), 35 (19%), and 10 (6%) had 2, 3, and 4 bands, respectively. All 35 patients with chronic hepatitis had a single band. All but 1 of 72 patients with cirrhosis had a single band. Multiple AFP bands on Con A affinity electrophoresis appear to be diagnostic of HCC. This method has a sensitivity of 76%, a specificity of 99%, a positive predictive value of 99%, and a negative predictive value of 71% for detecting HCC. The number of AFP bands correlated with serum AFP concentration and tumor size in patients with HCC. CONCLUSIONS This assay is useful for distinguishing HCC from benign chronic liver diseases.

UI MeSH Term Description Entries
D008103 Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules. Cirrhosis, Liver,Fibrosis, Liver,Hepatic Cirrhosis,Liver Fibrosis,Cirrhosis, Hepatic
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D003208 Concanavalin A A MANNOSE/GLUCOSE binding lectin isolated from the jack bean (Canavalia ensiformis). It is a potent mitogen used to stimulate cell proliferation in lymphocytes, primarily T-lymphocyte, cultures.
D003937 Diagnosis, Differential Determination of which one of two or more diseases or conditions a patient is suffering from by systematically comparing and contrasting results of diagnostic measures. Diagnoses, Differential,Differential Diagnoses,Differential Diagnosis
D004586 Electrophoresis An electrochemical process in which macromolecules or colloidal particles with a net electric charge migrate in a solution under the influence of an electric current. Electrophoreses
D005260 Female Females

Related Publications

S Saitoh, and K Ikeda, and I Koida, and Y Suzuki, and M Kobayashi, and A Tsubota, and Y Arase, and K Chayama, and N Murashima, and H Kumada
Early diagnosis of hepatocellular carcinoma with lectin electrophoresis of serum alpha-fetoprotein.
January 1988, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
S Saitoh, and K Ikeda, and I Koida, and Y Suzuki, and M Kobayashi, and A Tsubota, and Y Arase, and K Chayama, and N Murashima, and H Kumada
Lectin affinity electrophoresis of alpha-fetoprotein in cancer diagnosis.
January 1989, Electrophoresis,
S Saitoh, and K Ikeda, and I Koida, and Y Suzuki, and M Kobayashi, and A Tsubota, and Y Arase, and K Chayama, and N Murashima, and H Kumada
Lectin affinity electrophoresis of alpha-fetoprotein. Increased specificity and sensitivity as a marker of hepatocellular carcinoma.
June 1992, Journal of chromatography,
S Saitoh, and K Ikeda, and I Koida, and Y Suzuki, and M Kobayashi, and A Tsubota, and Y Arase, and K Chayama, and N Murashima, and H Kumada
Combined serum hepatoma-specific alpha-fetoprotein and circulating alpha-fetoprotein-mRNA in diagnosis of hepatocellular carcinoma.
November 2006, Hepatobiliary & pancreatic diseases international : HBPD INT,
S Saitoh, and K Ikeda, and I Koida, and Y Suzuki, and M Kobayashi, and A Tsubota, and Y Arase, and K Chayama, and N Murashima, and H Kumada
Serum alpha-fetoprotein and hepatocellular carcinoma size.
January 1989, The Journal of nuclear medicine and allied sciences,
S Saitoh, and K Ikeda, and I Koida, and Y Suzuki, and M Kobayashi, and A Tsubota, and Y Arase, and K Chayama, and N Murashima, and H Kumada
Serum-alpha 1-fetoprotein in hepatocellular carcinoma.
August 1974, Lancet (London, England),
S Saitoh, and K Ikeda, and I Koida, and Y Suzuki, and M Kobayashi, and A Tsubota, and Y Arase, and K Chayama, and N Murashima, and H Kumada
Utility of lentil lectin affinity of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma.
August 1996, Journal of hepatology,
S Saitoh, and K Ikeda, and I Koida, and Y Suzuki, and M Kobayashi, and A Tsubota, and Y Arase, and K Chayama, and N Murashima, and H Kumada
Value of serum alpha-fetoprotein and ferritin in the diagnosis of hepatocellular carcinoma.
January 1986, Oncology,
S Saitoh, and K Ikeda, and I Koida, and Y Suzuki, and M Kobayashi, and A Tsubota, and Y Arase, and K Chayama, and N Murashima, and H Kumada
Quantification and utility of monosialylated alpha-fetoprotein in the diagnosis of hepatocellular carcinoma with nondiagnostic serum total alpha-fetoprotein.
July 2002, Clinical chemistry,
S Saitoh, and K Ikeda, and I Koida, and Y Suzuki, and M Kobayashi, and A Tsubota, and Y Arase, and K Chayama, and N Murashima, and H Kumada
Serum alpha-fetoprotein as a biochemical marker for hepatocellular carcinoma.
September 1972, Cancer research,
Copied contents to your clipboard!